Victory Capital Management Inc. Purchases 216 Shares of Chemed Corp. (CHE)
Victory Capital Management Inc. raised its position in shares of Chemed Corp. (NYSE:CHE) by 17.7% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,434 shares of the company’s stock after purchasing an additional 216 shares during the quarter. Victory Capital Management Inc.’s holdings in Chemed Corp. were worth $293,000 as of its most recent SEC filing.
Several other institutional investors have also recently added to or reduced their stakes in the business. BlackRock Inc. grew its stake in shares of Chemed Corp. by 145,760.9% during the 1st quarter. BlackRock Inc. now owns 1,955,994 shares of the company’s stock valued at $357,341,000 after purchasing an additional 1,954,653 shares during the period. Vanguard Group Inc. grew its stake in shares of Chemed Corp. by 7.5% during the 1st quarter. Vanguard Group Inc. now owns 1,795,773 shares of the company’s stock valued at $328,070,000 after purchasing an additional 125,018 shares during the period. Neuberger Berman Group LLC grew its stake in shares of Chemed Corp. by 2.2% during the 1st quarter. Neuberger Berman Group LLC now owns 1,060,403 shares of the company’s stock valued at $193,725,000 after purchasing an additional 23,306 shares during the period. Acadian Asset Management LLC grew its stake in shares of Chemed Corp. by 1.3% during the 2nd quarter. Acadian Asset Management LLC now owns 579,170 shares of the company’s stock valued at $118,454,000 after purchasing an additional 7,636 shares during the period. Finally, State Street Corp grew its stake in shares of Chemed Corp. by 9.1% during the 1st quarter. State Street Corp now owns 445,367 shares of the company’s stock valued at $81,370,000 after purchasing an additional 37,085 shares during the period. Institutional investors and hedge funds own 96.96% of the company’s stock.
Chemed Corp. (NYSE CHE) opened at 187.96 on Wednesday. The company’s 50 day moving average price is $193.25 and its 200-day moving average price is $196.09. Chemed Corp. has a 52 week low of $132.92 and a 52 week high of $216.01. The company has a market capitalization of $3.01 billion, a P/E ratio of 46.63 and a beta of 1.14.
Chemed Corp. (NYSE:CHE) last announced its quarterly earnings results on Tuesday, July 25th. The company reported $2.15 earnings per share for the quarter, beating the consensus estimate of $1.89 by $0.26. The company had revenue of $415.06 million during the quarter, compared to analysts’ expectations of $407.56 million. Chemed Corp. had a return on equity of 26.18% and a net margin of 4.16%. Chemed Corp.’s quarterly revenue was up 6.3% on a year-over-year basis. During the same period last year, the business earned $1.80 earnings per share. Equities research analysts expect that Chemed Corp. will post $8.21 earnings per share for the current year.
The business also recently declared a quarterly dividend, which was paid on Friday, September 1st. Investors of record on Monday, August 14th were given a dividend of $0.28 per share. This is a boost from Chemed Corp.’s previous quarterly dividend of $0.26. This represents a $1.12 annualized dividend and a yield of 0.60%. The ex-dividend date was Thursday, August 10th. Chemed Corp.’s dividend payout ratio (DPR) is currently 28.07%.
In related news, Director George J. Walsh III purchased 1,000 shares of Chemed Corp. stock in a transaction that occurred on Monday, June 26th. The stock was bought at an average cost of $204.56 per share, for a total transaction of $204,560.00. Following the completion of the transaction, the director now owns 7,908 shares in the company, valued at $1,617,660.48. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Kevin J. Mcnamara sold 15,000 shares of Chemed Corp. stock in a transaction that occurred on Friday, July 28th. The shares were sold at an average price of $201.16, for a total value of $3,017,400.00. Following the transaction, the insider now owns 173,801 shares of the company’s stock, valued at $34,961,809.16. The disclosure for this sale can be found here. 5.32% of the stock is currently owned by company insiders.
CHE has been the subject of a number of recent research reports. BidaskClub downgraded Chemed Corp. from a “buy” rating to a “hold” rating in a research note on Wednesday, August 2nd. Zacks Investment Research upgraded Chemed Corp. from a “hold” rating to a “buy” rating and set a $213.00 price objective for the company in a research note on Wednesday, August 23rd. Royal Bank Of Canada reiterated a “hold” rating and set a $208.00 price objective on shares of Chemed Corp. in a research note on Wednesday, July 5th. Oppenheimer Holdings, Inc. boosted their price objective on Chemed Corp. from $200.00 to $220.00 and gave the company an “outperform” rating in a research note on Thursday, July 27th. Finally, TheStreet downgraded Chemed Corp. from a “b+” rating to a “c+” rating in a research note on Tuesday, July 25th. Two investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Chemed Corp. has an average rating of “Buy” and an average price target of $215.00.
Chemed Corp. Company Profile
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Corp. (NYSE:CHE).
Receive News & Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related companies with MarketBeat.com's FREE daily email newsletter.